Pfizer investors have seen brighter days—and then the last three years happened. Pfizer's share price has plummeted 51% over ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

Pfizer’s stock is catching a cold, slipping $0.24 to land near $24.16 while option traders wrap themselves in bearish ...

This was the stock's third consecutive day of losses.

According to Berenberg’s analysis, last year Novo Nordisk and Eli Lilly generated a RORI of 26 per cent and 24 per cent, ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

My final reason for buying more Pfizer stock is that I'll get paid nicely to wait and see if the drugmaker lives up to Wall Street's growth outlook. Pfizer's forward dividend yield currently stands at ...

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

the stock appears undervalued based on its Fair Value estimates, suggesting potential upside for investors. This comprehensive analysis examines Pfizer’s current position, recent performance ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Pfizer demonstrated strong financial performance ... will be crucial in shaping its future market position and stock performance. With a beta of 0.57 indicating lower volatility than the market ...